Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Fusion Pharmaceuticals (FUSN) Stock Forecast & Price Target

Fusion Pharmaceuticals logo
Get the Latest News and Ratings for FUSN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Fusion Pharmaceuticals and its competitors.

Sign Up

FUSN Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
7 Buy rating(s)
Hold
13 Hold rating(s)
13 Hold rating(s)
13 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$20.25$20.25$20.25$11.17
Forecasted Upside-6.03% Downside-6.03% Downside-6.03% Downside133.61% Upside
Consensus Rating
Hold
Hold
Hold
Buy

FUSN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FUSN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fusion Pharmaceuticals Stock vs. The Competition

TypeFusion PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.07
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-6.03% Downside26,931.55% Upside9.81% Upside
News Sentiment Rating
Neutral News

See Recent FUSN News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/16/2024TD Cowen
4 of 5 stars
 Reiterated RatingBuy ➝ Hold
3/20/2024Bloom Burton
2 of 5 stars
D. Martin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/20/2024B. Riley
4 of 5 stars
Y. Zhi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$13.00 ➝ $23.00+8.75%
3/20/2024Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
3/20/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Sector Perform$16.00 ➝ $21.00-0.85%
3/19/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
F. Khurshid
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/19/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$11.00 ➝ $21.00-0.05%
3/19/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$10.00 ➝ $21.00+0.05%
3/19/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingStrong-Buy ➝ Market Perform
3/19/2024Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/19/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hsieh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/19/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$24.00+14.29%
3/19/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$17.00 ➝ $21.00+97.37%
1/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$13.00 ➝ $15.00+77.94%
1/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$19.00 ➝ $10.00+201.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:37 AM ET.


FUSN Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Fusion Pharmaceuticals is $20.25, with a high forecast of $24.00 and a low forecast of $15.00.

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FUSN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FUSN, but not buy additional shares or sell existing shares.

According to analysts, Fusion Pharmaceuticals's stock has a predicted downside of -6.03% based on their 12-month stock forecasts.

Analysts like Fusion Pharmaceuticals less than other "medical" companies. The consensus rating for Fusion Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FUSN compares to other companies.


This page (NASDAQ:FUSN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners